BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25195656)

  • 1. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
    Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
    Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
    Gagelmann N; Badbaran A; Beelen DW; Salit RB; Stölzel F; Rautenberg C; Becker H; Radujkovic A; Panagiota V; Bogdanov R; Christopeit M; Park Y; Nibourel O; Luft T; Koldehoff M; Corsten M; Heuser M; Finke J; Kobbe G; Platzbecker U; Robin M; Scott BL; Kröger N
    Blood Adv; 2021 Mar; 5(6):1760-1769. PubMed ID: 33755092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
    Bataller A; Gener-Ricos G; Almanza-Huante E; Chien KS; Urrutia S; Bazinet A; Rodriguez-Sevilla JJ; Hammond D; Sasaki K; Takahashi K; DiNardo CD; Ravandi F; Borthakur G; Kadia TM; Kanagal-Shamanna R; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
    Blood Adv; 2024 Jun; 8(11):2695-2706. PubMed ID: 38513082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
    Patnaik MM; Tefferi A
    Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
    Patnaik MM; Wassie EA; Padron E; Onida F; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Komrokji R; Tefferi A; Solary E
    Blood Cancer J; 2015 Jan; 5(1):e270. PubMed ID: 25555161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.
    Patnaik MM; Wassie EA; Lasho TL; Hanson CA; Ketterling R; Tefferi A
    Am J Hematol; 2015 May; 90(5):411-6. PubMed ID: 25645147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
    Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
    Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
    Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
    Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
    Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
    Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
    Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
    Tefferi A; Elliott M; Pardanani A
    Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
    Wassie E; Finke C; Gangat N; Lasho TL; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Br J Haematol; 2015 Apr; 169(1):71-6. PubMed ID: 25521305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.
    Meggendorfer M; Haferlach T; Alpermann T; Jeromin S; Haferlach C; Kern W; Schnittger S
    Haematologica; 2014 Dec; 99(12):e244-6. PubMed ID: 25239264
    [No Abstract]   [Full Text] [Related]  

  • 19. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.
    Padron E; Garcia-Manero G; Patnaik MM; Itzykson R; Lasho T; Nazha A; Rampal RK; Sanchez ME; Jabbour E; Al Ali NH; Thompson Z; Colla S; Fenaux P; Kantarjian HM; Killick S; Sekeres MA; List AF; Onida F; Komrokji RS; Tefferi A; Solary E
    Blood Cancer J; 2015 Jul; 5(7):e333. PubMed ID: 26230957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
    Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
    Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.